[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 13,389 Class A ordinary shares through Charles Schwab & Co., Inc. on 09/05/2025, with an aggregate market value of $477,497.00. The shares were acquired the same day by employee stock option exercise and the payment method is listed as broker payment for cashless exercise. The filing lists multiple prior sales by the same seller, Eben Tessari, between 06/09/2025 and 09/04/2025, including several larger transactions reported on 06/11/2025, 08/05/2025 and 09/04/2025. Outstanding shares are shown as 43,472,928.

Insights

Financial Analyst

TL;DR Insider exercised options and is selling a modest block; prior sales by the same insider are frequent and substantially larger on some dates.

The filing documents a 13,389-share proposed sale valued at $477,497 following a same-day employee stock option exercise and a cashless exercise settlement. For investors, this is a routine disclosure of insider liquidity rather than an operational update about the company. The disclosure is timely and provides specific trade dates and gross proceeds for recent sales, which helps trace insider disposition activity but does not by itself indicate company performance changes.

Corporate Governance Expert

TL;DR Repeated insider sales are material to governance narrative; must be monitored but are disclosed in compliance with Rule 144.

The filing shows multiple disclosed sales by Eben Tessari across June through September 2025, including several large transactions. While the current Form 144 documents a single relatively small proposed sale, the pattern of prior disposals is relevant to shareholder perception of insider confidence. The notice includes required attestation language regarding material nonpublic information, and the mechanics of acquisition and cashless exercise are clearly stated.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	13389	477497.00	43472928	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	09/05/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			13389	09/05/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/09/2025	10319	313453.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/10/2025	15506	472239.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/11/2025	45042	1374277.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/16/2025	17300	489171.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	07/14/2025	18900	542860.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/05/2025	138614	4602409.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/18/2025	16200	547070.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/03/2025	15091	535778.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/04/2025	85271	3028740.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by KNSA disclose?

The Form 144 discloses a proposed sale of 13,389 Class A ordinary shares on 09/05/2025 valued at $477,497, acquired via an employee stock option exercise and to be sold through Charles Schwab & Co.

Who is the seller named in the filing for KNSA?

The filing and prior sales list Eben Tessari as the person selling shares, with an address reported as 100 Hayden Ave, Lexington MA.

How were the shares acquired according to the filing?

The 13,389 shares were acquired on 09/05/2025 by employee stock option exercise and the payment was handled via broker payment for cashless exercise.

Does the filing show other recent sales by the insider?

Yes; the filing lists multiple sales by the same person between 06/09/2025 and 09/04/2025, with individual gross proceeds reported for each transaction.

What exchange will the shares be sold on?

The proposed sale is to be executed on NASDAQ through Charles Schwab & Co., Inc.